BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 16, 2005
View Archived Issues
Aphton's Insegia Misses In Pancreatic Cancer Phase III
Aphton Corp.'s stock fell more than 45 percent Tuesday following news that its lead pancreatic cancer drug, Insegia, failed to meet the primary endpoint in a Phase III trial. (BioWorld Today)
Read More
Vertex, Avalon Sign $73M Cancer Drug Agreement
Read More
Kinase Inhibitor Profiling Method Gives New Therapeutic Insights
Read More
Crawford Receives Bush's Nomination As FDA Head
Read More
Other News To Note
Read More